603439.SH
三力制药
SSE · Healthcare · Biotechnology · CN
CNY 12.12
−2.34%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.7B | 2.1B | 1.6B | 1.2B |
| Cost of Revenue | 478.9M | 511.5M | 650.0M | 436.3M | 339.5M |
| Gross Profit | 1.2B | 1.2B | 1.5B | 1.2B | 861.8M |
| Operating Expenses | |||||
| R&D Expense | 22.9M | 27.9M | 46.5M | 30.6M | 17.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 129.9M | 147.4M | 147.4M | 86.5M | 55.4M |
| Selling & Marketing Expense | 821.3M | 800.9M | 941.9M | 792.7M | 562.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.0B | 1.0B | 1.2B | 925.6M | 645.7M |
| Cost and Expenses | 1.5B | 1.5B | 1.8B | 1.4B | 985.2M |
| Operating Income (EBIT) | 68.8M | 64.5M | 326.2M | 335.8M | 225.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 71.3M | 67.8M | 325.0M | 334.0M | 222.6M |
| Income Tax Expense | 20.5M | 19.6M | 45.2M | 39.2M | 30.6M |
| Bottom Line | |||||
| Net Income | 48.7M | 46.3M | 274.0M | 292.7M | 201.3M |
| Earnings from Cont. Ops | 50.8M | 48.2M | 279.8M | 294.9M | 193.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 48.7M | 46.3M | 274.0M | 292.7M | 201.3M |
| Per Share | |||||
| Basic EPS | CN¥0.12 | CN¥0.11 | CN¥0.67 | CN¥0.71 | CN¥0.49 |
| Diluted EPS | CN¥0.12 | CN¥0.11 | CN¥0.67 | CN¥0.71 | CN¥0.49 |
| Revenue Per Share | CN¥4.15 | CN¥4.05 | CN¥5.24 | CN¥3.97 | CN¥2.92 |
| Shares | |||||
| Basic Shares Outstanding | 403.7M | 420.5M | 409.0M | 412.3M | 410.8M |
| Diluted Shares Outstanding | 403.7M | 420.5M | 409.0M | 412.3M | 410.8M |
| Profitability Metrics | |||||
| EBITDA | — | 137.7M | 401.4M | 372.9M | 243.0M |
| D&A | — | 73.1M | 75.1M | 37.1M | 17.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026